This study from 2017 - 2019 compares the outcomes for oncology and non-oncology appraisals conducted...
Read moreA targeted drug has been accepted for routine use on the NHS in England for some adults with untreat...
Read moreNICE was the first EU HTA body to provide their assessment of Kymriah for ALL, publishing their opin...
Read moreAdults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS in Scot...
Read moreRoche has stolen a march on market leader Keytruda by gaining the first immuno-oncology approval in ...
Read moreA new game changing treatment for people with multiple myeloma will now be available on the NHS in E...
Read moreConclusion: Blincyto has significant clinical benefits, but that further evidence on cost-effective...
Read moreNICE's final appraisal indicates that Roche has offered the NHS a discount on the drug, which carrie...
Read moreCancer drug prices are rising rapidly, and profit margins for pharmaceutical companies reach upwards...
Read moreThe only CAR-T cell therapy available for NHS patients in England and Wales for two distinct blood c...
Read more